SG11201706727XA - Methods, compositions, and kits for treatment of cancer - Google Patents
Methods, compositions, and kits for treatment of cancerInfo
- Publication number
- SG11201706727XA SG11201706727XA SG11201706727XA SG11201706727XA SG11201706727XA SG 11201706727X A SG11201706727X A SG 11201706727XA SG 11201706727X A SG11201706727X A SG 11201706727XA SG 11201706727X A SG11201706727X A SG 11201706727XA SG 11201706727X A SG11201706727X A SG 11201706727XA
- Authority
- SG
- Singapore
- Prior art keywords
- kits
- cancer
- compositions
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562118350P | 2015-02-19 | 2015-02-19 | |
US201562150235P | 2015-04-20 | 2015-04-20 | |
PCT/US2016/018634 WO2016134234A1 (en) | 2015-02-19 | 2016-02-19 | Methods, compositions, and kits for treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201706727XA true SG11201706727XA (en) | 2017-09-28 |
Family
ID=56689191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201706727XA SG11201706727XA (en) | 2015-02-19 | 2016-02-19 | Methods, compositions, and kits for treatment of cancer |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160243228A1 (en) |
EP (1) | EP3258966A4 (en) |
JP (2) | JP6774421B2 (en) |
KR (1) | KR20170137717A (en) |
CN (1) | CN107635583A (en) |
AU (2) | AU2016219917B2 (en) |
BR (1) | BR112017017700A2 (en) |
CA (1) | CA2976638A1 (en) |
IL (1) | IL253979B (en) |
MX (1) | MX2017010595A (en) |
SG (1) | SG11201706727XA (en) |
WO (1) | WO2016134234A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX345909B (en) | 2009-03-25 | 2017-02-22 | Genentech Inc | Anti-fgfr3 antibodies and methods using same. |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
WO2015144808A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations of an fgfr inhibitor and an igf1r inhibitor |
KR102479693B1 (en) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | Combinations |
JOP20200201A1 (en) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
MX2018003564A (en) | 2015-09-23 | 2018-06-18 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer. |
LT3353177T (en) | 2015-09-23 | 2020-08-25 | Janssen Pharmaceutica Nv | Tricyclic heterocycles for the treatment of cancer |
CN110785184A (en) * | 2017-02-06 | 2020-02-11 | 雷尼尔医疗公司 | Methods, compositions and kits for treating cancer |
CN108440673B (en) * | 2018-04-08 | 2021-08-17 | 海南医学院 | Fc fusion protein PD1/FGFR1 and application thereof |
CA3131880A1 (en) * | 2019-03-01 | 2020-09-10 | Fusion Pharmaceuticals Inc. | Methods and compositions for treating cancer |
US20200277387A1 (en) * | 2019-03-01 | 2020-09-03 | Rainier Therapeutics, Inc. | Methods and compositions for treating cancer |
CN114466662A (en) * | 2019-09-26 | 2022-05-10 | 詹森药业有限公司 | Use of FGFR inhibitors in cancers with genetically altered FGFR to enhance patient response to immune checkpoint inhibitors in a sequential therapy setting |
AU2021327387A1 (en) | 2020-08-21 | 2023-05-04 | Genzyme Corporation | Fgfr3 antibodies and methods of use |
WO2022092085A1 (en) * | 2020-10-28 | 2022-05-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Pharmaceutical composition for treating tumors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR073770A1 (en) * | 2008-10-20 | 2010-12-01 | Imclone Llc | ISOLATED ANTIBODY THAT LINKS SPECIFICALLY WITH, AND INDUCES THE DEGRADATION OF THE RECEPTOR-3 OF THE HUMAN FIBROBLAST GROWTH FACTOR (FGFR-3), FGFR-3 HUMAN LINK FRAGMENT OF THE SAME, PHARMACEUTICAL COMPOSITION AND PRODUCT COMPOSITION |
MX345909B (en) * | 2009-03-25 | 2017-02-22 | Genentech Inc | Anti-fgfr3 antibodies and methods using same. |
WO2012088266A2 (en) * | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
AR091649A1 (en) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
KR20150037876A (en) * | 2012-07-27 | 2015-04-08 | 제넨테크, 인크. | Methods of treating fgfr3 related conditions |
US9873740B2 (en) * | 2013-07-16 | 2018-01-23 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors |
-
2016
- 2016-02-19 AU AU2016219917A patent/AU2016219917B2/en active Active
- 2016-02-19 CN CN201680022780.7A patent/CN107635583A/en active Pending
- 2016-02-19 EP EP16753128.4A patent/EP3258966A4/en not_active Withdrawn
- 2016-02-19 CA CA2976638A patent/CA2976638A1/en active Pending
- 2016-02-19 SG SG11201706727XA patent/SG11201706727XA/en unknown
- 2016-02-19 KR KR1020177025882A patent/KR20170137717A/en not_active Application Discontinuation
- 2016-02-19 JP JP2017544657A patent/JP6774421B2/en active Active
- 2016-02-19 MX MX2017010595A patent/MX2017010595A/en unknown
- 2016-02-19 BR BR112017017700A patent/BR112017017700A2/en active Search and Examination
- 2016-02-19 WO PCT/US2016/018634 patent/WO2016134234A1/en active Application Filing
- 2016-02-19 US US15/048,030 patent/US20160243228A1/en not_active Abandoned
-
2017
- 2017-08-14 IL IL253979A patent/IL253979B/en active IP Right Grant
-
2020
- 2020-10-02 JP JP2020167443A patent/JP7122357B2/en active Active
-
2022
- 2022-01-13 AU AU2022200196A patent/AU2022200196A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6774421B2 (en) | 2020-10-21 |
BR112017017700A2 (en) | 2018-07-31 |
CA2976638A1 (en) | 2016-08-25 |
KR20170137717A (en) | 2017-12-13 |
EP3258966A1 (en) | 2017-12-27 |
MX2017010595A (en) | 2018-11-12 |
JP7122357B2 (en) | 2022-08-19 |
CN107635583A (en) | 2018-01-26 |
IL253979A0 (en) | 2017-10-31 |
EP3258966A4 (en) | 2018-07-25 |
IL253979B (en) | 2021-06-30 |
WO2016134234A1 (en) | 2016-08-25 |
JP2021020909A (en) | 2021-02-18 |
AU2016219917B2 (en) | 2021-12-16 |
AU2016219917A1 (en) | 2017-09-07 |
AU2022200196A1 (en) | 2022-02-10 |
US20160243228A1 (en) | 2016-08-25 |
JP2018507220A (en) | 2018-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL258955A (en) | Compositions and methods for treatment of cancer | |
IL253979B (en) | Methods, compositions, and kits for treatment of cancer | |
IL267247B (en) | Compositions and methods for treating cancer | |
HK1251409A1 (en) | Methods of treating cancer | |
IL304820A (en) | Compositions and methods for treating cancer | |
EP3393475A4 (en) | Methods of treating cancer | |
IL266053A (en) | Compositions and methods for treating ezh2-mediated cancer | |
EP3377516A4 (en) | Methods and compositions for treating cancer | |
EP3166640A4 (en) | Combination therapy compositions and methods for treating cancers | |
HK1247931A1 (en) | Compositions and methods for diagnosis and treatment of cancer | |
EP3200815A4 (en) | Methods and compositions for treating cancer | |
EP3353204A4 (en) | Methods and compositions for treatment of cancer | |
EP3347025A4 (en) | Methods and compositions for cancer treatment | |
IL256523A (en) | Compositions and methods for treating cancer | |
EP3325006A4 (en) | Methods of treating cd166-expressing cancer | |
IL268163A (en) | Methods, compositions, and kits for treatment of cancer | |
EP3328372A4 (en) | Compositions and methods of treating cancer | |
SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
EP3154544A4 (en) | Compositions and methods for treating cancers | |
IL255638A (en) | Compositions and methods for treating cancer | |
EP3185910A4 (en) | Methods and compositions for the treatment of cancer | |
EP3154952A4 (en) | Methods and compositions for treatment of her-positive cancers | |
EP3268028A4 (en) | Compositions and methods for treating cancer | |
HK1250958A1 (en) | Compositions and methods for treating cancer | |
EP3160591A4 (en) | Compositions and methods for treating cancer |